



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LI et al.

#181/2

Application Serial No.: 09/348,815

Group Art Unit: 1635

Filed: July 8, 1999

Examiner: Zara, J.

Title: **Connective Tissue Growth Factor 2**

Atty. Docket No.: PF126P1D1

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references BA to BD listed on the attached Form PTO/SB/08A. A copy of each of reference(s) BA to BD is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in an International Search Report mailed November 5, 2001, in connection with a related U.S. application, submitted herewith as reference BE. The required fee of \$180.00 is also transmitted herewith with the concurrently filed Fee Transmittal.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 315-2723

Enclosures
JKE/JMM/rmr